BOLINGBROOK, Ill., July 26,
2021 /PRNewswire/ -- ATI Physical Therapy – ("ATI" or the
"Company") (NYSE: ATIP), the largest independent outpatient
physical therapy provider in the United States, today reported
financial results for the second quarter ended June 30, 2021.

"I would like to thank our nationwide team for their dedication,
service and tireless effort providing the highest quality clinical
care to our patients that makes ATI a leader in the large and
growing physical therapy industry," said Labeed Diab, Chief Executive Officer. "We are
seeing growing demand for ATI's services, and visit volume
increased during the second quarter. However, the acceleration of
attrition among our therapists in the second quarter and continuing
into the third quarter, combined with the intensifying competition
for clinicians in the labor market, prevented us from being able to
meet the demand we have and increased our expectations for labor
costs. We are implementing a range of actions related to
compensation, staffing levels and other items to retain and attract
therapists across our platform to meet our currently underserved
patient demand. We expect therapist headcount to be below
previously anticipated levels for 2021 which, combined with
elevated costs for therapists and an unfavorable revenue mix, has
caused us to reduce our forecast for 2021. We continue to have
confidence in the underlying fundamentals driving our business and
our ability to leverage our strong position in the market to drive
growth and value over time."
Joe Jordan, Chief Financial
Officer of ATI Physical Therapy, added, "We reduced our leverage
and enhanced our financial flexibility as a result of completing
the business combination. We believe that the combination of our
strong balance sheet and underlying industry fundamentals, along
with the actions we are taking to restore our staffing levels, will
enable us to navigate the headwinds we are experiencing and
position the company for long-term growth."
As previously announced, on June 16,
2021, ATI completed its business combination with Fortress
Value Acquisition Corp. II ("FVAC II"), a special purpose
acquisition company. Immediately following, the Company began
operating as "ATI Physical Therapy, Inc." and its Class A common
stock was listed on the New York Stock Exchange. In connection with
the closing of the business combination, ATI utilized proceeds from
the transaction to reduce its outstanding gross debt to $561.2
million.
Second Quarter 2021 Performance Summary
Summary of key performance results in second quarter 2021, in
addition to prior sequential quarter and prior comparative quarter,
were as follows ($s in millions, except on per visit basis):
|
Q2 2021
|
Q1 2021
|
Q2 2020
|
Visits per Day
(000's)
|
21.6
|
19.5
|
12.6
|
growth rate, quarter
over
quarter
|
10.5%
|
--
|
--
|
growth rate, year
over
year
|
70.6%
|
--
|
--
|
|
|
|
|
Rate per
Visit
|
$106.26
|
$107.56
|
$117.41
|
growth rate, quarter
over
quarter
|
(1.2)%
|
--
|
--
|
growth rate, year
over
year
|
(9.5)%
|
--
|
--
|
|
|
|
|
Net Operating
Revenue
|
$164.0
|
$149.1
|
$107.8
|
growth rate, quarter
over
quarter
|
10.0%
|
--
|
--
|
growth rate, year
over
year
|
52.1%
|
--
|
--
|
|
|
|
|
Clinic Salaries and
Related
Costs
|
$80.9
|
$80.7
|
$54.0
|
As % net operating
revenue
|
49.3%
|
54.1%
|
50.1%
|
|
|
|
|
Net (Loss) Income
before
Taxes
|
$(5.5)
|
$(28.3)
|
$8.2
|
Net (loss) income
before taxes margin
|
(3.4)%
|
(19.0)%
|
7.6%
|
|
|
|
|
Net (Loss) Income
(1)
|
--
|
$(17.8)
|
$4.6
|
Net (loss) income
margin
|
--
|
(12.0)%
|
4.3%
|
|
|
|
|
Adjusted EBITDA
(2)
|
$24.0
|
$5.6
|
$45.5
|
Adjusted EBITDA
margin
|
14.6%
|
3.8%
|
42.2%
|
|
|
|
|
Net (Decrease)
Increase in
Cash
|
$(7.1)
|
$(44.5)
|
$93.4
|
|
|
(1)
|
At this time, we are
not yet able to calculate Income tax expense without unreasonable
efforts, and accordingly, Net income (loss) for the quarter ended
June 30, 2021 and will provide such totals in our Quarterly Report
on Form 10-Q for the quarterly period ended June 30, 2021 when
filed. A reconciliation of our non-GAAP results to our GAAP results
is included in the accompanying tables. Please see "Non-GAAP
Financial Measures" and "Reconciliation of GAAP to Non-GAAP
Financial Measures."
|
(2)
|
A reconciliation of
our non-GAAP results to our GAAP results is included in the
accompanying tables. Please see "Non-GAAP Financial Measures" and
"Reconciliation of GAAP to Non-GAAP Financial Measures."
|
- Visits per Day ("VPD") were 21,569, compared to 19,520 in the
first quarter of 2021 and 12,643 in the second quarter of 2020, an
increase of 10.5% quarter over quarter and 70.6% year over year as
a result of continued volume increases as COVID-19 restrictions in
local markets evolved and referral levels improved, steadily
increasing demand for our services.
- Rate per Visit ("RPV") was $106.26, compared to $107.56 in the first quarter of 2021 and
$117.41 in the second quarter of
2020, a decrease of 1.2% quarter over quarter and 9.5% year over
year driven by a faster rebound in lower reimbursing vs. higher
reimbursing payors and state mix shift.
- Net operating revenue was $164.0
million, compared to $149.1
million in the first quarter of 2021 and $107.8 million in the second quarter of 2020, an
increase of 10.0% quarter over quarter and 52.1% year over year.
The increase was driven by higher patient visit volumes, partially
offset by lower RPV.
- Clinic salaries and related costs were $80.9 million, compared to $80.7 million in the first quarter of 2021 and
$54.0 million in the second quarter
of 2020. Clinic salaries and related costs as a percentage of net
operating revenue were 49.3%, compared to 54.1% in the first
quarter of 2021 and 50.1% in the second quarter of 2020. The
decreasing expense ratio was primarily driven by higher clinic
labor productivity.
- Net (loss) income before taxes was $(5.5) million, compared to $(28.3) million in the first quarter of 2021 and
$8.2 million in the second quarter of
2020. Net (loss) income before taxes margin was (3.4)%, compared to
(19.0)% in the first quarter of 2021 and 7.6% in the second quarter
of 2020.
- Net (loss) income was $(17.8)
million in the first quarter of 2021 and $4.6 million in the second quarter of 2020. Net
(loss) income margin was (12.0)% in the first quarter of 2021 and
4.3% in the second quarter of 2020. At this time, ATI is not yet
able to calculate income tax expense for the second quarter 2021
without unreasonable efforts and, accordingly, second quarter 2021
net income (loss) will not be reported until the company files its
quarterly report on Form 10-Q for the quarterly period ended
June 30, 2021.
- Adjusted EBITDA was $24.0
million, compared to $5.6
million in the first quarter of 2021 and $45.5 million (which includes CARES Act Provider
Relief Funds of $44.3 million) in the
second quarter of 2020. Adjusted EBITDA margin was 14.6%, compared
to 3.8% in the first quarter of 2021 and 1.1% (excluding CARES Act
Provider Relief Funds of $44.3
million) in the second quarter of 2020. The increase in
margin was primarily driven by higher clinic labor productivity and
the operating leverage inherent in our business model.
- Net (decrease) increase in cash was $(7.1) million, compared to $(44.5) million in the first quarter of 2021 and
$93.4 million in the second quarter
of 2020 (including $118.2 million of
cash flow resulting from the CARES Act Provider Relief Funds and
MAAPP).
Summary of key balance sheet items as of end of second quarter
2021 were as follows:
- Cash and cash equivalents totaled $90.6
million. The revolving credit facility was undrawn with
available capacity of $68.8 million,
net of usage by letters of credit.
- Gross debt totaled $559.1
million, and net debt (i.e. gross debt less $90.6 million of unrestricted cash) was
$468.5 million. With the latest
twelve months Adjusted EBITDA of $112.8
million as of June 30, 2021,
gross and net debt leverage ratios were 5.0x and 4.2x,
respectively.
Other notable achievements in the second quarter 2021 were as
follows:
- Opened 10 new clinics with locations primarily in Georgia, Massachusetts, and Texas; nine of which were de novo sites, and
one of which was an acqui-novo clinic.
- VPD per clinic was 24.3, compared to 22.2 in the first quarter
of 2021 and 14.6 in the second quarter of 2020, an increase of 9.5%
quarter over quarter and 66.4% year over year.
Medicare Accelerated and Advance Payment Program ("MAAPP")
and Deferred Social Security Taxes
Pursuant to the CARES Act, expansion of the Medicare Accelerated
and Advance Payment Program ("MAAPP") funds allowed healthcare
providers to apply to receive advanced payments for future Medicare
services, with the expectation that the advanced funds would offset
reimbursement from Medicare when such future services are provided
based on the terms of the program.
The Company applied for and attained approval from the Centers
for Medicare & Medicaid Services ("CMS") and received
$26.7 million of MAAPP funds in
April 2020. The Company repaid
$3.8 million in MAAPP funds in the
second quarter of 2021, and $22.6
million of the funds were recorded within accrued expenses
and other liabilities and $0.3
million within other non-current liabilities on the balance
sheet as of June 30, 2021.
In addition, the Company elected to defer depositing the
employer portion of the Social Security taxes for payments due from
March 27, 2020 through December 31, 2020, interest-free and
penalty-free. Related to these payments, as of June 30, 2021, $5.5
million is included in accrued expenses and other
liabilities and $5.5 million is
included in other non-current liabilities.
2021 Earnings Forecast
For full year 2021, ATI is now projecting revenue to be in the
range of $640 million to $670 million and Adjusted EBITDA to be in the
range of $60 million to $70 million, down from $731 million and $119
million, respectively. ATI does not intend to provide
revenue guidance as a future guidance metric. The revised
expectations reflect the impact of the following developments which
are partially offset by continued strong demand for ATI's
services:
- The acceleration of attrition in the second quarter and
continuing into the third quarter caused, in part, by changes made
during the COVID-19 pandemic related to compensation, staffing
levels and support for clinicians. ATI has taken swift actions to
offset those changes, but the company expects the impact of
attrition in the second and third quarters will impact overall
profitability for the year.
- Labor market dynamics that increased competition for the
available physical therapy providers in the workforce, creating
wage inflation and elevated employee attrition at ATI, negatively
affecting our ability to capitalize on continued customer
demand.
- Decrease in rate per visit primarily driven by continuing less
favorable payor and state mix when compared to pre-pandemic
profile, with general shift from workers compensation and auto
personal injury to commercial and government, and further impacted
by mix-shift out of higher reimbursement states.
Largely in response to the accelerated attrition, ATI is
lowering its estimate for new clinic openings, (i.e., de novo and
acqui-novo clinics), to be in the range of 55 to 65 clinics from 90
clinics. Our ability to achieve our revised forecast for the
remainder of 2021 depends upon a number of factors, including the
success of a number of steps being taken to significantly reduce
attrition of physical therapists and significant hiring of physical
therapists.
The Company has determined that the revision to its 2021
forecast constitutes an interim triggering event that requires
further analysis with respect to potential impairment to goodwill
and trade name intangible assets. Accordingly, the Company is
currently performing interim quantitative impairment testing during
the third quarter of 2021. If it is determined that the fair value
amounts are below the respective carrying amounts, the Company will
record an impairment charge which could be material.
Conference Call
ATI Physical Therapy will host a conference call to discuss
second quarter 2021 results on July 26,
2021 at 8:00 a.m. Eastern
Time. The conference call can be accessed via a live audio
webcast at Q2 2021 Earnings Conference Call. Information may also
be found on the Company's website at www.atipt.com. To join, please
access the web link at least 15 minutes early to register,
download and install any necessary audio software. A replay of the
call will be available via webcast for on-demand listening shortly
after the completion of the call, at the same web link, and will
remain available for approximately 90 days.
About ATI Physical Therapy
At ATI Physical Therapy, we are passionate about potential.
Every day, we restore it in our patients and activate it in our
team members in our approximate 900 locations across the U.S. With
outcomes from more than 2.5 million unique patient cases, ATI is
making strides in the industry by setting quality standards that
deliver predictable outcomes for our patients with musculoskeletal
(MSK) issues. ATI's offerings span across a broad spectrum for
MSK-related issues. From preventative services in the workplace and
athletic training support to home health, outpatient clinical
services and online physical therapy via its online platform,
CONNECT™, a complete list of our service offerings can be found at
ATIpt.com. ATI is based in Bolingbrook,
Illinois.
Category: Earnings
Forward-Looking Statements
All statements other than statements of historical facts
contained in this communication are forward-looking statements for
purposes of the safe harbor provisions under the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may generally be identified by the use of words such as
"believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect," "should," "would," "plan," "project,"
"forecast," "predict," "potential," "seem," "seek," "future,"
"outlook," "target" or other similar expressions (or the negative
versions of such words or expressions) that predict or indicate
future events or trends or that are not statements of historical
matters. These forward-looking statements include, but are not
limited to, statements regarding 2021 forecast and other estimates
of financial and performance metrics and market opportunity. These
statements are based on various assumptions, whether or not
identified in this communication, and on the current expectations
of ATI's management and are not predictions of actual performance.
These forward-looking statements are estimates only and are not
intended to serve as, and must not be relied on by any investor as,
a guarantee, an assurance or a definitive statement of fact or
probability. Actual events and circumstances are difficult or
impossible to predict and may differ from assumptions, and such
differences may be material. Many actual events and circumstances
are beyond the control of ATI. These forward-looking statements are
subject to a number of risks and uncertainties, including, but not
limited to:
(i)
|
changes in domestic
and foreign business, market, financial, political and legal
conditions, including shifts and trends in payor mix;
|
(ii)
|
the ability to
maintain the listing of the Company's securities on
NYSE;
|
(iii)
|
the ability of the
Company to realize the anticipated benefits of the business
combination;
|
(iv)
|
risks related to the
rollout of ATI's business strategy and the timing of expected
business milestones;
|
(v)
|
the effects of
competition on ATI's future business and the ability of ATI to grow
and manage growth profitably, maintain relationships with customers
and suppliers and retain its management and key
employees;
|
(vi)
|
the ability of the
Company to retain and to hire physical therapists consistent with
its business plan;
|
(vii)
|
the outcome of any
legal proceedings that may be instituted against the Company or any
of its directors or officers, following the announcement of the
business combination;
|
(viii)
|
the ability of the
Company to issue equity or equity-linked securities or obtain debt
financing in the future;
|
(ix)
|
risks related to
political and macroeconomic uncertainty;
|
(x)
|
the impact of the
global COVID-19 pandemic on any of the foregoing risks;
and
|
(xi)
|
those factors
discussed in FVAC II's definitive proxy statement relating to the
business combination filed with the SEC on May 14,
2021 under the heading "Risk Factors," and other documents
filed by FVAC II or ATI, or to be filed, with the SEC.
|
If any of these risks materialize or our assumptions prove
incorrect, actual results could differ materially from the results
implied by these forward-looking statements, including our forecast
update. There may be additional risks that ATI does not presently
know or that ATI currently believes are immaterial that could also
cause actual results to differ from those contained in the
forward-looking statements. In addition, the forward-looking
statements in this communication reflect ATI's expectations, plans
or forecasts of future events and views as of the date of this
communication. ATI anticipates that subsequent events and
developments will cause ATI's assessments with respect to these
forward-looking statements to change. However, while ATI may elect
to update these forward-looking statements at some point in the
future, ATI specifically disclaims any obligation to do so, unless
required by applicable law. These forward-looking statements should
not be relied upon as representing ATI's assessments as of any date
subsequent to the date of this press release. Accordingly, undue
reliance should not be placed upon the forward-looking
statements.
Non-GAAP Financial Measures
To supplement the Company's financial information presented in
accordance with GAAP and aid understanding of the Company's
business performance, the Company uses certain non-GAAP financial
measures, namely "Adjusted EBITDA" and "Adjusted EBITDA margin." We
believe Adjusted EBITDA and Adjusted EBITDA margin (i.e. Adjusted
EBITDA divided by Net Operating Revenue) assist investors and
analysts in comparing our operating performance across reporting
periods on a consistent basis by excluding items that we do not
believe are indicative of our core operating performance.
Information provided for the twelve months ended June 30, 2021 (or LTM) refers to the four-quarter
period ended June 30, 2021. We
regularly compute and review our key GAAP and non-GAAP measures on
a last twelve months basis as it is used by management and our
board of directors to assess our financial performance. Measures
calculated on an LTM basis are also frequently used by analysts,
investors, and other interested parties to evaluate companies in
our industry. All financial measures presented on an LTM basis are
derived from our consolidated financial statements and related
notes, except that information for the most recent quarter remains
subject to completion.
Management believes these non-GAAP financial measures are useful
to investors in highlighting trends in our operating performance,
while other measures can differ significantly depending on
long-term strategic decisions regarding capital structure, the tax
jurisdictions in which we operate and capital investments.
Management uses these non-GAAP financial measures to supplement
GAAP measures of performance in the evaluation of the effectiveness
of our business strategies, to make budgeting decisions, to
establish discretionary annual incentive compensation and to
compare our performance against that of other peer companies using
similar measures. Management supplements GAAP results with non-GAAP
financial measures to provide a more complete understanding of the
factors and trends affecting the business than GAAP results
alone.
Adjusted EBITDA and Adjusted EBITDA margin are not recognized
terms under GAAP and should not be considered as an alternative to
net income (loss) or the ratio of net income (loss) to net revenue
as a measure of financial performance, cash flows provided by
operating activities as a measure of liquidity, or any other
performance measure derived in accordance with GAAP. Additionally,
these measures are not intended to be a measure of cash available
for management's discretionary use as they do not consider certain
cash requirements such as interest payments, tax payments and debt
service requirements. The presentations of these measures have
limitations as analytical tools and should not be considered in
isolation, or as a substitute for analysis of our results as
reported under GAAP. Because not all companies use identical
calculations, the presentations of these measures may not be
comparable to other similarly titled measures of other companies
and can differ significantly from company to company.
We have reconciled Adjusted EBITDA to Net income (loss) for all
historical periods. We are not able to reconcile to Net income
(loss) for the period ended June 30,
2021 at this time, because the information necessary to
complete that reconciliation is not yet available without
unreasonable effort, and will provide such reconciliation in our
Quarterly Report on Form 10-Q for the quarterly period ended
June 30, 2021 when filed, and are not
able to provide a reconciliation for Adjusted EBITDA forecast for
future periods. Please see "Reconciliation of GAAP to Non-GAAP
Financial Measures" below for reconciliations of non-GAAP financial
measures used in this release to their most directly comparable
GAAP financial measures.
Investor Contact:
Joanne
Fong
SVP, Treasurer and Investor Relations
630-296-2222 x 7131
investors@atipt.com
Media Contact:
Clifton
O'Neal
Director, Corporate Communications
630-296-2223 x 7993
Clifton.Oneal@atipt.com
ATI Physical
Therapy Consolidated Condensed Operations Data ($
in thousands)
(unaudited)
(preliminary)
|
|
|
Three Months
Ended
|
|
Six Months
Ended
|
|
June 30,
2021
|
|
June 30,
2020
|
|
June 30,
2021
|
|
June 30,
2020
|
|
|
|
|
|
|
|
|
Net patient
revenue
|
$
|
146,679
|
|
|
$
|
95,003
|
|
|
$
|
278,950
|
|
|
$
|
259,942
|
|
Other
revenue
|
17,354
|
|
|
12,751
|
|
|
34,145
|
|
|
30,550
|
|
Net operating
revenue
|
164,033
|
|
|
107,754
|
|
|
313,095
|
|
|
290,492
|
|
|
|
|
|
|
|
|
|
Clinic operating
costs:
|
|
|
|
|
|
|
|
Salaries and related
costs
|
80,917
|
|
|
53,966
|
|
|
161,571
|
|
|
149,315
|
|
Rent, clinic supplies,
contract labor and other
|
44,079
|
|
|
38,708
|
|
|
87,375
|
|
|
84,137
|
|
Provision for doubtful
accounts
|
3,585
|
|
|
3,941
|
|
|
10,756
|
|
|
9,961
|
|
Total clinic operating
costs
|
128,581
|
|
|
96,615
|
|
|
259,702
|
|
|
243,413
|
|
Selling, general and
administrative expenses
|
26,391
|
|
|
24,791
|
|
|
51,117
|
|
|
48,262
|
|
Operating income
(loss)
|
9,061
|
|
|
(13,652)
|
|
|
2,276
|
|
|
(1,183)
|
|
Change in fair value
of warrant liability
|
(4,539)
|
|
|
—
|
|
|
(4,539)
|
|
|
—
|
|
Change in fair value
of contingent common shares liability
|
(20,948)
|
|
|
—
|
|
|
(20,948)
|
|
|
—
|
|
Loss on settlement of
redeemable preferred stock
|
14,037
|
|
|
—
|
|
|
14,037
|
|
|
—
|
|
Interest expense,
net
|
15,632
|
|
|
17,683
|
|
|
31,719
|
|
|
35,541
|
|
Interest expense on
redeemable preferred stock
|
4,779
|
|
|
4,604
|
|
|
10,087
|
|
|
8,981
|
|
Other expense
(income), net
|
5,626
|
|
|
(44,103)
|
|
|
5,779
|
|
|
(43,971)
|
|
(Loss) income before
taxes
|
(5,526)
|
|
|
8,164
|
|
|
(33,859)
|
|
|
(1,734)
|
|
Income tax expense
(1)
|
|
|
|
3,568
|
|
|
|
|
|
1,776
|
|
Net income
(loss)(1)
|
|
|
|
$
4,596
|
|
|
|
|
|
$
(3,510)
|
|
|
|
(1)
|
At this time, we are
not yet able to calculate Income tax expense, and accordingly, Net
income (loss) for the periods ended June 30, 2021 and will provide
such totals in our Quarterly Report on Form 10-Q for the quarterly
period ended June 30, 2021 when filed.
|
ATI Physical
Therapy Reconciliation of GAAP to Non-GAAP Financial
Measures ($ in thousands)
(unaudited)
(preliminary)
|
|
|
Twelve months
ended
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|
|
June 30,
2021
|
2021
|
|
2020
|
2021
|
|
2020
|
|
(Loss) income
before taxes
|
$
|
(30,358)
|
|
$
|
(5,526)
|
|
|
$
|
8,164
|
|
$
|
(33,859)
|
|
|
$
|
(1,734)
|
|
Income tax
expense(1)
|
|
|
|
|
|
|
|
|
3,568
|
|
|
|
|
|
|
|
1,776
|
|
Net income
(loss)(1)
|
|
|
|
|
|
|
|
|
4,596
|
|
|
|
|
|
|
(3,510)
|
|
Plus
(minus):
|
|
|
|
|
|
|
|
|
Net income
attributable to non-
controlling interest
|
(4,449)
|
|
(1,252)
|
|
|
(1,855)
|
|
(2,561)
|
|
|
(3,185)
|
|
|
Income tax
expense(1)
|
|
|
|
|
|
3,568
|
|
|
|
|
1,776
|
|
|
Interest expense,
net
|
65,469
|
|
15,632
|
|
|
17,683
|
|
31,719
|
|
|
35,541
|
|
|
Interest expense on
redeemable
preferred stock
|
20,137
|
|
4,779
|
|
|
4,604
|
|
10,087
|
|
|
8,981
|
|
|
Depreciation and
amortization
expense
|
38,720
|
|
9,149
|
|
|
9,763
|
|
18,768
|
|
|
19,748
|
|
|
EBITDA
|
$
|
89,519
|
|
$
|
22,782
|
|
|
|
$
|
38,359
|
|
$
|
24,154
|
|
|
|
$
|
59,351
|
|
|
Changes in fair value
of warrant
liability and contingent common
shares liability(2)
|
(25,487)
|
|
(25,487)
|
|
|
—
|
|
(25,487)
|
|
|
—
|
|
|
Loss on debt
extinguishment(3)
|
5,534
|
|
5,534
|
|
|
—
|
|
5,534
|
|
|
—
|
|
|
Loss on settlement of
redeemable
preferred stock(4)
|
14,037
|
|
14,037
|
|
|
—
|
|
14,037
|
|
|
—
|
|
|
Transaction and
integration costs(5)
|
10,320
|
|
3,580
|
|
|
100
|
|
6,498
|
|
|
968
|
|
|
Share-based
compensation
|
4,593
|
|
3,112
|
|
|
466
|
|
3,616
|
|
|
960
|
|
|
Pre-opening de novo
costs(6)
|
1,578
|
|
441
|
|
|
268
|
|
875
|
|
|
862
|
|
|
Reorganization and
severance
costs(7)
|
5,477
|
|
—
|
|
|
1,255
|
|
362
|
|
|
2,397
|
|
|
Business optimization
costs(8)
|
2,969
|
|
—
|
|
|
5,011
|
|
—
|
|
|
7,408
|
|
|
Charges related to
lease
terminations(9)
|
4,253
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
Adjusted
EBITDA
|
$
112,793
|
|
$
23,999
|
|
|
$
45,459
|
|
$
29,589
|
|
|
$
71,946
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
We have reconciled
Adjusted EBITDA to Net income (loss) for all historical periods. At
this time, we are not yet able to reconcile to Net income (loss)
for the periods ended June 30, 2021 and will provide such
reconciliation in our Quarterly Report on Form 10-Q for the
quarterly period ended June 30, 2021 when filed.
|
(2)
|
Represents non-cash
charges related to the change in the estimated fair value of
Warrants, Earnout Shares and Vesting Shares
|
(3)
|
Represents charges
related to the derecognition of the proportionate amount of
remaining unamortized deferred financing costs and original
issuance discount associated with the partial repayment of the
first lien term loan and derecognition of the unamortized original
issuance discount associated with the full repayment of the
subordinated second lien term loan
|
(4)
|
Represents loss on
settlement of redeemable preferred stock based on the value of cash
and equity provided to preferred stockholders in relation to the
outstanding redeemable preferred stock liability at the time of the
closing of the Business Combination
|
(5)
|
Represents costs
related to the Company's business combination with FVAC II, clinic
acquisitions and acquisition-related integration and consulting and
planning costs related to preparation to operate as a public
company
|
(6)
|
Represents expenses
associated with renovation, equipment and marketing costs relating
to the start-up and launch of new locations incurred prior to
opening
|
(7)
|
Represents severance,
consulting and other costs related to discrete initiatives focused
on reorganization and delayering of the Company's labor model,
management structure and support functions
|
(8)
|
Represents
non-recurring costs to optimize our platform and ATI transformative
initiatives. Costs primarily related to duplicate costs driven by
IT and Revenue Cycle Management conversions, labor related costs
during the transition of key positions and other incremental costs
of driving optimization initiatives
|
(9)
|
Represents charges
related to lease terminations prior to the end of term for
corporate facilities no longer in use
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ati-physical-therapy-reports-second-quarter-2021-results-revises-2021-forecast-301340669.html
SOURCE ATI Physical Therapy